Member Info for Hurst10

Meanwhile size buyers moving in, will be one heck of a trading Friday, with a lovely week coming up.

Tapestry to buy Michael Kors

When one consider the following: The Chemotherapy Market Size was valued at USD 9.5 billion in 2022. It is projected to reach USD 17.61 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031) and you then look at the upcoming news flow from the company, the share price is behaving like

“ the calm before the tempest” and we could easily see

Avacta trading limit up on the day!

Novartis etc. also residing at White City by Imperial College, will have a couple of busy months ahead.

You mean £40 pounds

The famous line from the movie world,have no doubt been used at Avacta’s board meetings.

The company realises now how big the AVA’s will be and how big Avacta Therapeutics inc. will be on the street.

It is worth reminding ourselves, on the company’s website , the manuscript has been amended, with the AGM presentation slides now have a line in the diagnostic section, talking about a future spin off that division.

The future value of the therapeutic division will be at such a completely different level and could join ARM holdings as one of the hottest IPO’s of the year, with “ strategic shareholders “ on board.

What price you pay today, will prove to be completely irrelevant in a month’s time. As long as you are on board and do not leave.

Doubt it is heading for Switzerland, more likely NY.

Let us have the buy print

It appears they are back!

Very soon, as I have repeatedly said, Avacta will prove to be the best thing out of Cambridge( they did have offices and labs there) since Arm holdings!

Focus on the record M&A biotech business going on over there and the premium being paid.

Some of the funds up 15% since Mid July

Some of the funds up 15% since Mid July

Suspect an avalanche of news flow, corporate events and the press being all over Avacta and patient investors will find themselves multiple times rewarded.

This is only just the beginning with several announcements on its way.

Plenty of after hours prints.

Size buyers enjoying themselves.

Nice tickets coming into the opening of NY

150/ ticket going through

On the AGM Presentation desks,If one would again look at slide 15, headlines for the diagnostic division and read the following line: “ Potential spin-out opportunity “, which clearly indicates to me that the company now have a better idea of how big and commercial the therapeutic division will be and hence the IPO, away from the diagnostic division.

The second half will no longer carry “if “ but “when” events will happen, which will completely revalue the company!

Sales print of 130/ earlier, a true transaction I wonder?

Last hour’s trading of buyers picking up what they can and MM lifting the offer price through 100p, will be difficult to get size over the last hour, just in case we have some noise from the company tomorrow AM!

When Avacta, had their lab and office located in Cambridge, I always said that Avacta was the best thing out of Cambridge since Arm holdings.

Arm holdings now planning $60bill IPO, on the biotech side, let us see at what valuation Avacta’s upcoming IPO will be priced at, post announcements and any license deals.

If one re-read previous research notes, where the analyst would apply a” once we have AVA6000/AVA3996 and the FDA and successful trials” up and running, well then one would have a potential valuation, substantially above current estimates.

Let us hope it makes it to the IPO of the Therapeutic business before one of the majors moves on, with a multi billion dollar bid!

The large global healthcare companies are watching this one very closely.